<DOC>
	<DOC>NCT02262637</DOC>
	<brief_summary>Study to evaluate efficacy and tolerability of Micardis速/MicardisPlus速 under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists</brief_summary>
	<brief_title>Micardis速 / MicardisPlus速 Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
	<criteria>Age &gt;= 18 years Age &lt; 18 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>